Wellness Clinical Research is recognizing Principal Investigator Lucky Flores, MD, for his participation in the ECOSPOR clinical development program.
The 2024 peer-reviewed article, “Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI,” names Lucky Flores among the ECOSPOR III and ECOSPOR IV investigators.
Integrated Phase 3 recurrent CDI research
The publication evaluated safety and efficacy data from two Phase 3 trials of VOWST oral spores, previously known as SER-109, following standard-of-care antibiotics for recurrent Clostridioides difficile infection.
The integrated analysis assessed treatment-emergent adverse events and recurrent CDI rates through follow-up.
Dr. Flores included in the investigator group
The full-text article includes a contributor section on behalf of the ECOSPOR III and ECOSPOR IV investigators and explicitly lists Lucky Flores.
This provides a direct public record of Dr. Flores’s participation in the Phase 3 program.